PCSK9 and metabolic syndrome: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) who’s use has been widely accepted in both familial homozygous and heterozygous hypercholesterolemias and their variants (9, 10), have recently been recognized as a promising adjunctive therapy for DM and dyslipidemia at high risk of CV events (8).